Cardiac toxicity of cancer therapy;Kardiotoksyczność leczenia przeciwnowotworowego

Polski Merkuriusz Lekarski

Volumn 13, Issue 73, 2002, Pages 79-85

  Łacko, Aleksandra ^a   Włodarska, Iwona ^a   Zymliński, Robert ^a   Mazur, Grzegorz ^a   Wróbel, Tomasz ^a   Gisterek, Iwona ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Anthracyclines; Cardiotoxicity; Chemotherapy; Dexrazoxan; Radiotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOXORUBICIN; RAZOXANE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOVASCULAR AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG FORMULATION; HEART MUSCLE INJURY; HEART PROTECTION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PATIENT SELECTION; QUALITY OF LIFE; RADIATION INJURY; REVIEW; RISK FACTOR; SOFT TISSUE SARCOMA; ADJUVANT THERAPY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONGESTIVE CARDIOMYOPATHY; FEMALE; NEOPLASM; RADIATION RESPONSE; SARCOMA;

ANTIBIOTICS, ANTHRACYCLINE; BREAST NEOPLASMS; CARDIOMYOPATHY, CONGESTIVE; CARDIOVASCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENGLISH ABSTRACT; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RADIOTHERAPY, ADJUVANT; RAZOXANE; RISK FACTORS; SARCOMA; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHY, DILATED; HUMANS;

EID: 0036024119     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Anthracycline cardiomyopathy monitored by pathomorphologic changes
2. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease
3. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy
4. Long term cardiac morbidity and mortality in randomized trial in pre- and postiperative radiation therapy versus surgery alone in primary breast cancer
5. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
6. Postmastectomy radiotherapy: Toxicities and techniques to reduce them
7. Use of cardiac troponine T levels as an indicator of doxorubicin induced cardiotoxicity
8. Cardiotoxicity and cardioprotection during chemotherapy
9. Risk factors for doxorubicine-induced heart failure
10. Treatment with angiotensin-converting-enzyme inhibitor for epirubicine-induced dilated cardiomyopathy
11. Is enalapril beneficial in doxorubicine-treated long-term survivors of childhood cancer?
12. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas
13. Sensitivity and specificity of radionuclide ejection fraction in doxorubicin cardiotoxicity
14. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
15. Niepoźa̧dane nastȩpstwa chemioterapii nowotworów - Sposoby ich zwalczania i zapobiegania
16. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
17. Mortality from myocardial infarction after adjuvant radiotherapy of breast cancer in the surveillance, epidemiology, and endresults cancer registries
18. Design and interpretation of clinical trials that evaluate agents that may offer protection from toxic effects of cancer chemotherapy
19. Myocardial function in children and adolescents after therapy with antracyclines and chest irradiation
20. Late cardiotoxicity after malignant bone tumor
21. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
22. Mortality by laterality of the primary tumor among 55 000 breast cancer patients from the Swedish Cancer Registry
23. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
24. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer
25. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
26. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
27. Strategies for reduction of anthracycline cardiac toxicity
28. Prolongation of isovolumeric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfuction in humans
29. Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer
30. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
31. Cardiac effect following adiuvant chemiotherapy and breast irradiation in operable breast cancer
32. Multicenter randomized controllrd clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
33. Studies on adriamycin using a weekly regiment demonstrating its clinical effectiveness and lac of cardiac toxicity
34. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
35. Clinical Assessment of the structure activity relationship of anthracyclines and related derivatives